Article
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine plus Pioglitazone and All-Trans Retinoic Acid
2025-12-25
Abstract excerpt
The search for new therapeutic principles is essential for treating relapsed/refractory (r/r) acute myeloid leukemia (AML). Novel principles include genome-agnostic differentiation induction, controlling AML-triggering inflammation, potentiating the immune response and 'normalizing' AML metabolism. This review summarizes data from a phase I study (10 patients, pts) and three case reports (7pts) on the tr...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bae58561-e28d-522e-96c4-5fa480489e9d
- DOI
- 10.20944/preprints202512.2313.v1
